Skip to main content

Cenix, Metanomics Reach Research Agreement

NEW YORK (GenomeWeb) – Contract research organization Cenix BioScience this week announced a research framework agreement with metabolite services and biomarker firm Metanomics Health.

As the first assignment, Cenix will perform a target validation project for Metanomics for an undisclosed disease indication. Cenix will use its expertise in high-content screening based on the Definiens XD image analysis platform for the comprehensive functional characterization of target genes designated by Metanomics, it said.

Financial and other terms of the deal were not disclosed.

Cenix has operations in Germany and the US and specializes in genome-scale gene modulation studies and high-throughput, high-content pharmacology. Metanomics, a BASF Group company based in Germany, provides metabolite profiling services and develops metabolomic biomarkers.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.